These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. High risk of malignancy in patients with incidentally discovered adrenal masses: accuracy of adrenal imaging and image-guided fine-needle aspiration cytology. Lumachi F; Borsato S; Tregnaghi A; Marino F; Fassina A; Zucchetta P; Marzola MC; Cecchin D; Bui F; Iacobone M; Favia G Tumori; 2007; 93(3):269-74. PubMed ID: 17679462 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of quantitative parameters for distinguishing pheochromocytoma from other adrenal tumors. Ohno Y; Sone M; Taura D; Yamasaki T; Kojima K; Honda-Kohmo K; Fukuda Y; Matsuo K; Fujii T; Yasoda A; Ogawa O; Inagaki N Hypertens Res; 2018 Mar; 41(3):165-175. PubMed ID: 29348428 [TBL] [Abstract][Full Text] [Related]
5. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements; 2002 Feb 4-6; 19(2):1-25. PubMed ID: 14768652 [TBL] [Abstract][Full Text] [Related]
6. Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary? Sane T; Schalin-Jäntti C; Raade M J Clin Endocrinol Metab; 2012 Jun; 97(6):2077-83. PubMed ID: 22492870 [TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and follow-up of Korean patients with adrenal incidentalomas. Cho YY; Suh S; Joung JY; Jeong H; Je D; Yoo H; Park TK; Min YK; Kim KW; Kim JH Korean J Intern Med; 2013 Sep; 28(5):557-64. PubMed ID: 24009451 [TBL] [Abstract][Full Text] [Related]
8. Optimal follow-up strategies for adrenal incidentalomas: reappraisal of the 2016 ESE-ENSAT guidelines in real clinical practice. Hong AR; Kim JH; Park KS; Kim KY; Lee JH; Kong SH; Lee SY; Shin CS; Kim SW; Kim SY Eur J Endocrinol; 2017 Dec; 177(6):475-483. PubMed ID: 28870984 [TBL] [Abstract][Full Text] [Related]